|Bid||0.4100 x 1100|
|Ask||0.4210 x 1100|
|Day's range||0.3903 - 0.4393|
|52-week range||0.3900 - 5.5900|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||13 Nov 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||6.00|
RICHMOND, Va., January 18, 2022--Aditxt, Inc. ("Aditxt," or the "Company") (Nasdaq: ADTX), a biotech innovation company with a mission to advance humanity’s transition to the "Age of Immunity," has submitted two EUA applications for AditxtScore™ for COVID-19. This lab-developed blood test provides a more comprehensive profile of the body’s immune response to COVID-19.
RICHMOND, Va., January 14, 2022--Aditxt, Inc. ("Aditxt" or the "Company") (Nasdaq: ADTX) announced today it is participating in Edison Group’s Open House Event, scheduled to take place virtually this month.
RICHMOND, Va., January 12, 2022--Aditxt, Inc. ("Aditxt" or the "Company") (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced it will host an online business update townhall meeting with Amro Albanna, Co-Founder & CEO on Tuesday, January 18th from 2:00 to 3:00 pm ET.